Cargando…

HEMOLYTIC ASSAY OF THE NINTH COMPLEMENT COMPONENT: ELEVATION AND DEPLETION IN RHEUMATIC DISEASES

An effective molecule titration for the ninth component of complement in the biologic fluids of man was developed using EAC1-8 cells produced by treating EAC14 cells with a chromatographic fraction of human serum containing C2, C3, C5, C6, C7, and C8. Kinetic studies of the interaction of EAC1-8 wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruddy, Shaun, Everson, Lloyd K., Schur, Peter H., Austen, K. Frank
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 1971
Materias:	Rheumatoid Arthritis and Other Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2139086/ https://www.ncbi.nlm.nih.gov/pubmed/19867371

Ejemplares similares

Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis
por: Su, Yu-Jih, et al.
Publicado: (2023)

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Reddy, Venkat, et al.
Publicado: (2015)

Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study
por: Mehta, Bella, et al.
Publicado: (2019)

‘Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?’
por: Goodman, Susan M, et al.
Publicado: (2020)

B cell depletion impairs vaccination-induced CD8(+) T cell responses in a type I interferon-dependent manner
por: Graalmann, Theresa, et al.
Publicado: (2021)

The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial
por: Winkler, Aaron, et al.
Publicado: (2021)

Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated
por: Raadsen, Reinder, et al.
Publicado: (2023)

Is rheumatoid arthritis a risk factor for acute coronary syndrome also among individuals at elevated risk, such as individuals presenting with acute chest pain?
por: Svensson, Per, et al.
Publicado: (2020)

Association of Distinct Fine Specificities of Anti−Citrullinated Peptide Antibodies With Elevated Immune Responses to Prevotella intermedia in a Subgroup of Patients With Rheumatoid Arthritis and Periodontitis
por: Schwenzer, Anja, et al.
Publicado: (2017)

Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial
por: Bechman, Katie, et al.
Publicado: (2018)

Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis
por: Gärtner, M, et al.
Publicado: (2016)

Infliximab Versus Conventional Combination Treatment and Seven‐Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial
por: Eriksson, Jonas K., et al.
Publicado: (2016)

Intermetatarsal bursitis is frequent in patients with established rheumatoid arthritis and is associated with anti-cyclic citrullinated peptide and rheumatoid factor
por: Hammer, Hilde Berner, et al.
Publicado: (2019)

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
por: Norvang, Vibeke, et al.
Publicado: (2018)

Comparative analyses of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyses from the ARCTIC study
por: Holten, Karen, et al.
Publicado: (2018)

Validation of a machine learning approach to estimate Clinical Disease Activity Index Scores for rheumatoid arthritis
por: Spencer, Alison K., et al.
Publicado: (2021)

Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers
por: Palomäki, Antti, et al.
Publicado: (2021)

Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals
por: Ponchel, Frederique, et al.
Publicado: (2022)

Risk Factors for Falls in Adults With Rheumatoid Arthritis: A Prospective Study
por: Stanmore, Emma K, et al.
Publicado: (2013)

Fall Incidence and Outcomes of Falls in a Prospective Study of Adults With Rheumatoid Arthritis
por: Stanmore, Emma K, et al.
Publicado: (2013)

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
por: Furst, D E, et al.
Publicado: (2015)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Trends of lymphoma incidence in US veterans with rheumatoid arthritis, 2002–2017
por: Singh, Namrata, et al.
Publicado: (2020)

Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
por: Low, Audrey S. L., et al.
Publicado: (2016)

Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
por: Kaeley, Gurjit S., et al.
Publicado: (2016)

A Multi‐Biomarker Disease Activity Score and the Choice of Second‐Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure
por: Hambardzumyan, Karen, et al.
Publicado: (2017)

Impending radiographic erosive progression over the following year in a cohort of consecutive patients with inflammatory polyarthritis: prediction by serum biomarkers
por: Carrier, Nathalie, et al.
Publicado: (2020)

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
por: Paulshus Sundlisæter, Nina, et al.
Publicado: (2022)

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial
por: Hambardzumyan, Karen, et al.
Publicado: (2016)

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population
por: Mercer, Louise K., et al.
Publicado: (2013)

Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients
por: Duarte, Catia, et al.
Publicado: (2021)

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries
por: Finckh, A, et al.
Publicado: (2015)

Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?
por: Mongin, Denis, et al.
Publicado: (2019)

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy
por: Sundin, Ulf, et al.
Publicado: (2021)

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment
por: Holten, Karen, et al.
Publicado: (2022)

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
por: Burmester, Gerd R, et al.
Publicado: (2017)

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
por: Winthrop, Kevin L., et al.
Publicado: (2019)

Age affects joint space narrowing in patients with early active rheumatoid arthritis
por: Matthijssen, X M E, et al.
Publicado: (2016)

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
por: Nordberg, Lena Bugge, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sa89j7cv2b3l98o2il8m589hvp